drugset / Trial / NCT01947777
Phase 1 Study in Healthy Subjects to Evaluate the Effect of Rifampin on the Pharmacokinetics of IPI-145
NaSingle-groupOpen-labelBasic science
Summary
To evaluate the effect of rifampin, a cytochrome P450 3A (CYP3A) inducer, on the pharmacokinetics (PK) of IPI-145; to assess the safety and tolerability of IPI-145 when administered with rifampin in healthy subjects
Timeline
- Start
- 2013-10
- Primary completion
- 2013-11
- Completion
- 2013-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Duvelisib | Small molecule | 25 mg | Oral |
| Subject | Rifampin | Small molecule | 600 mg | Oral |
Indications
No indication recorded.